Biomarkers Identify Acute Kidney Injury in Emergency Patients
(NEW YORK, NY, January 6, 2012) – Acute kidney injury (AKI) has severe consequences, with a 25 to 80 percent risk of in-hospital death. Researchers have found a way to diagnose AKI using a urine test, enabling emergency departments to identify these high-risk patients when they first arrive at the hospital. The study will be published online on January 9, 2012, in the Journal of the American College of Cardiology.
Physicians typically measure a patient’s creatinine levels to determine kidney function. But creatinine levels can remain normal for several hours after acute kidney damage, and an accurate assessment requires measurements taken over a period of 1-3 days. This limits their usefulness in an emergency room. Urinary biomarkers, however, require only a half hour or so to obtain a measure of the severity of kidney damage, explains Thomas Nickolas, MD, MS, assistant professor of clinical medicine at Columbia University College of Physicians and Surgeons and a kidney specialist at NewYork-Presbyterian Hospital/The Allen Hospital.
In an international, multi-center study, researchers from Columbia University Medical Center at NewYork-Presbyterian Hospital/The Allen Hospital; Staten Island University Hospital; and Charité-Universitätsmedizin, Max Delbruck Center for Molecular Medicine, and Helios Clinics, Berlin, Germany, took a single measure of five urinary biomarkers from 1,635 emergency room patients upon their admission to the hospital. Although all five biomarkers were elevated in cases of iAKI (intrinsic AKI, the most severe form of AKI), the biomarker called uNGAL was most accurate in the diagnosis of iAKI and best predicted its duration and severity. uNGAL, along with another biomarker, called Kim-1, most accurately predicted death or the need to start dialysis during hospitalization. uNGAL was discovered at NewYork-Presbyterian/Columbia University and at Cincinnati Children’s Hospital; it was measured in this study by Abbott’s ARCHITECT-NGAL assay, which is available commercially outside the US.
“The ability to identify acute kidney damage while the patient is in triage is especially important in busy urban hospitals, where patients cannot wait for repetitive measures of creatinine and are frequently lost to follow-up,” said senior author Jonathan Barasch, MD, PhD, associate professor of medicine and of anatomy and cell biology at Columbia University College of Physicians and Surgeons and a kidney specialist at NewYork-Presbyterian Hospital/The Allen Hospital. “The use of urinary biomarkers could also be of great use to the military, at disaster sites, and in other situations where quick medical decisions must be made.”
"Combining urinary biomarkers such as uNGAL with the current standard marker creatinine will significantly improve the identification of patients at risk of death or dialysis in the hospital," added Dr. Kai Schmidt-Ott, MD, a kidney specialist at Charité Berlin, research group leader at the Max Delbrück Center for Molecular Medicine, and adjunct assistant professor at Columbia University Medical Center. "Identifying these patients at the earliest possible time in the emergency room may enable us to introduce new treatment options to improve their outcomes."
The study’s authors are Thomas L. Nickolas (CUMC/NYP), Kai M. Schmidt-Ott (Max Delbruck Center for Molecular Medicine) who contributed equally and Pietro Canetta (CUMC/NYP), Catherine Foster (CUMC), Eugenia Singer (Max Delbruck Center for Molecular Medicine), Meghan Sise (CUMC), Antje Elger (Max Delbruck Center for Molecular Medicine), Omar Maarouf (Staten Island University Hospital), David Antonio Sola-Del Valle (CUMC/NYP), Matthew O’Rourke (CUMC/NYP), Evan Sherman (CUMC/NYP), Peter Lee (CUMC), Abdallah Geara (CUMC/NYP), Philip Imus (CUMC/NYP), Achuta Guddati (CUMC), Allison Polland (CUMC), Wasiq Rahman (CUMC), Saban Elitok (Max Delbruck Center for Molecular Medicine), Nasir Malik (CUMC), James Giglio (CUMC/NYP), Suzanne El-Sayegh (Staten Island University Hospital), Prasad Devarajan (Cincinnati Children’s Hospital), Sudarshan Hebbar (Abbott Laboratories), Subodh J. Saggi (Staten Island University Hospital), Barry Hahn (Staten Island University Hospital), Ralph Kettritz (Max Delbruck Center for Molecular Medicine), Friedrich C. Luft (Max Delbruck Center for Molecular Medicine), and Jonathan Barasch (CUMC/NYP).
The study was supported by the NIH (DK073462) and the Deutsche Forschungsgemeinschaft.
Abbott supported the collection, handling, and testing of urine samples and performed part of the diagnostic tests but without access to patient data. KF received travel support from Abbott to coordinate the study. Abbott did not contribute to the study design, data analysis, or preparation of the final manuscript. Columbia University and Cincinnati Children’s Hospital have licensed uNGAL to Abbott for use in the diagnosis of AKI. KMSO and TLN have consultation agreements with Abbott. KMSO and SE have participated in advisory board meetings for Tardis Medical Consultancy, Amsterdam, Netherlands. SH has been employed by Abbott. PD has received lecture honoraria from Abbott and Biosite.
Columbia University Medical Center provides international leadership in basic, pre-clinical, and clinical research; in medical and health sciences education; and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians and Surgeons was the first institution in the country to grant the M.D. degree and is among the most selective medical schools in the country. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest in the United States. For more information, please visit www.cumc.columbia.edu.
NewYork-Presbyterian Hospital, based in New York City, is the nation’s largest not-for-profit, non-sectarian hospital, with 2,409 beds. The Hospital has nearly 2 million inpatient and outpatient visits in a year, including 12,797 deliveries and 195,294 visits to its emergency departments. NewYork-Presbyterian’s 6,144 affiliated physicians and 19,376 staff provide state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine at five major centers: NewYork-Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children’s Hospital, NewYork-Presbyterian/The Allen Hospital and NewYork-Presbyterian Hospital/Westchester Division. One of the most comprehensive health care institutions in the world, the Hospital is committed to excellence in patient care, research, education and community service. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S.News & World Report. The Hospital has academic affiliations with two of the nation’s leading medical colleges: Weill Cornell Medical College and Columbia University College of Physicians and Surgeons. For more information, visit www.nyp.org.